Celldex Therapeutics (NASDAQ:CLDX) Earns Overweight Rating from Cantor Fitzgerald

Cantor Fitzgerald reaffirmed their overweight rating on shares of Celldex Therapeutics (NASDAQ:CLDX) in a report released on Monday, Benzinga reports. The firm currently has a $67.00 price target on the biopharmaceutical company’s stock.

Several other analysts have also issued reports on CLDX. Wolfe Research initiated coverage on Celldex Therapeutics in a research note on Tuesday, June 11th. They issued an outperform rating and a $51.00 target price for the company. Stifel Nicolaus initiated coverage on Celldex Therapeutics in a research note on Tuesday, June 18th. They issued a buy rating and a $58.00 target price for the company. HC Wainwright reissued a buy rating and set a $80.00 price objective on shares of Celldex Therapeutics in a research note on Monday, August 12th. Finally, Wells Fargo & Company increased their price objective on Celldex Therapeutics from $35.00 to $37.00 and gave the company an equal weight rating in a research note on Monday, August 12th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of Moderate Buy and a consensus price target of $63.83.

Celldex Therapeutics Trading Up 1.5 %

CLDX stock opened at $41.85 on Monday. The stock has a market cap of $2.77 billion, a price-to-earnings ratio of -14.68 and a beta of 1.56. The company’s 50 day moving average is $38.45 and its 200 day moving average is $38.78. Celldex Therapeutics has a 1-year low of $22.11 and a 1-year high of $53.18.

Celldex Therapeutics (NASDAQ:CLDX) last issued its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.54) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.59) by $0.05. The business had revenue of $2.50 million during the quarter, compared to analyst estimates of $1.13 million. Celldex Therapeutics had a negative return on equity of 23.66% and a negative net margin of 1,809.18%. As a group, sell-side analysts forecast that Celldex Therapeutics will post -2.5 EPS for the current fiscal year.

Institutional Trading of Celldex Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Celldex Therapeutics in the second quarter worth $76,000. Headlands Technologies LLC bought a new position in Celldex Therapeutics in the first quarter worth $147,000. CANADA LIFE ASSURANCE Co raised its holdings in Celldex Therapeutics by 26.4% in the first quarter. CANADA LIFE ASSURANCE Co now owns 4,570 shares of the biopharmaceutical company’s stock worth $192,000 after purchasing an additional 955 shares in the last quarter. Ameritas Investment Partners Inc. raised its holdings in Celldex Therapeutics by 34.3% in the first quarter. Ameritas Investment Partners Inc. now owns 6,198 shares of the biopharmaceutical company’s stock worth $260,000 after purchasing an additional 1,582 shares in the last quarter. Finally, Aigen Investment Management LP bought a new position in Celldex Therapeutics in the fourth quarter worth $251,000.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.